Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.60 |
| ▸ | F3 | P13726 | 1/20 | 0.60 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | GABRP | O00591 | 3/20 | 0.53 |
| ▸ | GABRD | O14764 | 3/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.53 |
| ▸ | GABRE | P78334 | 3/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22955917 | 0.89 | GPR84 (0.54) | F7F3GPR84NR4A2GABRP | |
| SCHEMBL22956048 | 0.85 | GPR84 (0.51) | F7F3GPR84NR4A2CDC25B | |
| SCHEMBL11984941 | 0.85 | GPR84 (0.55) | GPR84CDC25BMEN1MAPTHTT | |
| SCHEMBL22955413 | 0.84 | F7 (0.57) | F7F3GPR84NR4A2GABRP | |
| SCHEMBL8530849 | 0.84 | GPR84 (0.77) | GPR84NR4A2CDC25BMEN1MAPT | |
| SCHEMBL29489280 | 0.84 | GPR84 (0.77) | GPR84NR4A2CDC25BMEN1MAPT | |
| SCHEMBL14111893 | 0.83 | CDC25B (0.54) | F7F3GPR84NR4A2NHERF1 | |
| SCHEMBL22955590 | 0.82 | F7 (0.61) | F7F3GPR84NR4A2GABRP | |
| SCHEMBL11903896 | 0.81 | NR4A2 (0.60) | GPR84NR4A2KDRMEN1MAPT | |
| SCHEMBL22955418 | 0.81 | GPR84 (0.47) | GPR84KDRCDC25BMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125348-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | OREGON STATE UNIVERSITY (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4710922-A2 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | Oregon State University (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4003337-B1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | UNIV OREGON STATE (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12473262-B2 | Aryl hydrocarbon receptor activators | OREGON STATE UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20220281824-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | OREGON STATE UNIVERSITY (US) | 2022-09-08 | — | — | US | disclosed |
| EP-4003337-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | Oregon State University (US) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281824-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | AHR, ARNT, NR0B1 | F7 4859/4885F3 3054/4885GPR84 86/4885 |
| US-20260125348-A1 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | AHR, ARNT, NR1H2 | F7 2352/4885F3 1288/4885GPR84 221/4885 |
| US-12473262-B2 | Aryl hydrocarbon receptor activators | AHR, ARNT, NR0B1 | F7 4859/4885F3 3054/4885GPR84 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.